Pharmacists in Brighton, Massachusetts


30 Pharmacists found in Brighton
female pharmacist

Randi Kowalczyk


Pharmacist
207 Market St, Brighton, MA 02135
617-254-0358    

female pharmacist

Rebecca Martinez, RPH.


Pharmacist
214 Market St, Brighton, MA 02135
617-787-5040     617-787-5834

female pharmacist

Robyn Holman


Pharmacist
1925 Commonwealth Ave, Brighton, MA 02135
412-287-0709    



female pharmacist

Sossy Yogurtian


Pharmacist
370 Western Ave, Brighton, MA 02135
617-782-1628     617-782-1269

male pharmacist

Dr. Steven P Lee


Pharmacist
207 Market St, Brighton, MA 02135
617-254-0358    

male pharmacist

Steven Leung


Pharmacist
8 Colborne Rd, Apt#1, Brighton, MA 02135
617-787-9798    

female pharmacist

Summer C Yeley, PHARMD


Pharmacist
207 Market St, Brighton, MA 02135
617-254-0358    

female pharmacist

Susan Graf, RPH


Pharmacist
207 Market St, Brighton, MA 02135
617-254-0358    

male pharmacist

Tian Jun Colin Ma


Pharmacist
1927 Beacon St, Brighton, MA 02135
617-738-6820    

female pharmacist

Tiffany Anna Wu


Pharmacist
1558 Commonwealth Ave, Brighton, MA 02135
617-566-2281    

female pharmacist

Trini Trang Truong, RPH


Pharmacist
427 Washington St, Brighton, MA 02135
617-783-2577    

female pharmacist

Uliana Demelo, PHARMD


Pharmacist
1558 Commonwealth Ave, Brighton, MA 02135
617-566-2281     617-232-4084

female pharmacist

Uyen Le-kong, PHARMD


Pharmacist
1558 Commonwealth Ave, Brighton, MA 02135
617-566-2281     617-232-4084

male pharmacist

Vinh Nguyen


Pharmacist
370 Western Ave, Brighton, MA 02135
617-782-1628     617-782-1269


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.